Печать
(+)-PENTAZOCINE - DEA SCHEDULE IV ITEM
Кол-во:
Цена по запросу
Товар оформляется под заказ
Печать
(+)-PENTAZOCINE - DEA SCHEDULE IV ITEM
Кол-во:
Цена по запросу
Товар оформляется под заказ
Печать
(+)-PENTAZOCINE - DEA SCHEDULE IV ITEM
Кол-во:
Цена по запросу
Товар оформляется под заказ
Description_x000D_
Biochem/physiol Actions_x000D_
σ receptor agonist; active enantiomer of pentazocine._x000D_
Features and Benefits_x000D_
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds, Approved Drugs, and Drug Candidates, click here._x000D_
Caution_x000D_
Photosensitive_x000D_
Reconstitution_x000D_
A 10 mM solution of (+)-pentazocine is prepared by warming 28.5 mg of (+)-pentazocine free base in 2 mL of 0.1N HCl with shaking or sonication. When all solids have dissolved, the solution is cooled to room temperature and diluted with 10 mL of pH 7 buffer. Solutions should be freshly prepared, since cooling below room temperature may result in precipitation.
Related Categories
Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, Excitatory Amino Acids - Opiod Agonists, Fluorination Ready Pharma-Developed Compounds, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, Membrane Protein Biology Tools, Neurobiology, Neuroscience, Opioid Agonists, Opioids, P-PH, Pharmacologicals, Proteins and Derivatives, Sanofi AventisMore... Quality Level
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
